learndrugs
Mental & Behavioral Health

Substance Use & Overdose

SUD High-yield Verified · Sep 2026

A substance use disorder is repeated use causing clinically significant distress or impairment, diagnosed by two or more of eleven criteria within twelve months — and overdose is the acute toxicity of that use, most lethally as opioid-induced respiratory depression.

The disorder behind pinpoint pupils and a respiratory rate of four, the titrate-to-breathing naloxone rule, the re-sedation window, the COWS score that gates the first buprenorphine dose, and the two stimulant rules that are the opposite of instinct — no restraints, no antipyretics.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 Dependence, tolerance and addiction are three different things

Start with the vocabulary, because the page is unusable without it. Dependence is physiological: "when a person suddenly stops using a drug, their body goes through withdrawal, a group of physical and mental symptoms that can range from mild to life-threatening." Addiction is behavioural: "the continued use of these drugs despite adverse consequences or events." And opioid use disorder is the diagnosis that spans them — chronic opioid use that causes real distress or impairs daily life, with "an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when opioids are discontinued. Thus, OUD can range from dependence on opioids to addiction."

The diagnostic criteria are one set applied to every substance. For opioids: repeated use within 12 months with two or more of continued use despite worsening physical or psychological health; continued use despite social and interpersonal consequences; decreased social or recreational activities; difficulty fulfilling duties at work or school; excessive time spent obtaining or recovering from use; more taken than intended; cravings; inability to cut down; tolerance; use despite danger; and withdrawal, or continued use to avoid it. Six or more indicates severe opioid use disorder — and the alcohol page uses the identical structure with the same severity cut-offs, which is the point: this is one criteria set wearing different substance names.

The mechanism that makes dependence so hard to escape is that it works in both directions. "Physical dependence on opioids may develop rapidly and is likely the result of many changes in mu-opioid receptors, including receptor desensitization, internalization, and signaling abnormalities… Thus, physical dependence on opioids creates both positive and negative reinforcement for continued opioid use." The drug is taken to feel good and to stop feeling terrible — and once the second reason takes over, "many opioid-dependent patients will seek continued access to opioids, by legal or illegal means, to prevent withdrawal." The receptor doing this is specific: opioids act at mu, delta and kappa G protein-coupled receptors that inhibit adenyl cyclase, and "the mu receptor is crucial for reinforcing the actions of opioids."

02 The opioid chain — from the receptor to the respiratory rate

Opioid overdose kills through one mechanism, and naloxone reverses that one mechanism. Naloxone "is indicated for the treatment of opioid toxicity, specifically to reverse respiratory depression from opioid use." The visible picture is the triad plus a late sign: unconsciousness or inability to awaken; pinpoint pupils; slow, shallow breathing with "choking sounds or a gurgling/snoring noise from a person who cannot be awakened," or respiratory arrest; and fingernails or lips turning blue or purple. The pupil is diagnostically load-bearing: "the presence of miosis in a prehospital patient with altered mental status is highly indicative of responsiveness to naloxone."

Withdrawal comes from one anatomical place, and knowing it explains an entire drug class. "The principal site in the brain that triggers the onset of opioid withdrawal syndrome is the locus coeruleus at the base of the brain. Neurons present in locus coeruleus are noradrenergic and have an increased number of opioid receptors… The noradrenergic activity in locus coeruleus neurons is a prime causative site of opioid withdrawal symptoms." At the cellular level the symptoms are "closely related to pathways of adenylyl cyclase superactivation-based central excitation." That is why an alpha-2 agonist works — lofexidine "binds to receptors on adrenergic neurons, which reduces sympathetic tone and decreases norepinephrine release."

And one sentence explains every precipitated withdrawal on this page. Withdrawal "can also be caused when a patient has an opioid in his/her system and is given an opioid partial agonist like buprenorphine or antagonists like naloxone or naltrexone." That single mechanism produces three different clinical traps: naloxone given in a full-reversal dose to a dependent patient, buprenorphine started before the patient is already in withdrawal, and naltrexone started before seven opioid-free days. Each one is iatrogenic, each one is avoidable, and each one is on the exam.

The opioid chain. Tolerance and dependence reinforce use from opposite directions, overdose kills through respiratory depression, and naloxone reverses it for a shorter time than the opioid lasts — while completed withdrawal sets up the next, deadlier use.

03 The stimulant chain — and the two rules that are the opposite of instinct

Stimulants work by flooding the monoamine systems, and the damage follows the flood. Amphetamines are "structural analogs of the neurotransmitter phenethylamine," regulating monoamine neurotransmission through trace amine-associated receptor 1 and inhibition of vesicular monoamine transporter 2. That receptor sits in the caudate, putamen, substantia nigra, nucleus accumbens, ventral tegmental area, locus ceruleus, amygdala and raphe nucleus — and "many of these areas play important roles in the development of addiction. Thus, the use of amphetamines begets the desire to continue using amphetamines." Route decides how fast the hit arrives and therefore how reinforcing it is: methamphetamine peaks 3 to 6 hours after oral ingestion, 5 to 10 minutes after nasal insufflation, and within 5 minutes when smoked, with bioavailability of "70% or greater" by those routes.

The vascular damage is a separate mechanism from the sympathetic surge. Downstream effects "may lead to increased reactive oxygen species, mitochondrial dysfunction, and alterations in intracellular calcium… implicated in the accelerated development of cardiovascular disease. Amphetamines also cause necrotizing vasculitis of small- and medium-sized blood vessels, which can yield a myriad of end-organ complications — strokes and neurodegenerative diseases, coronary artery disease, ischemic bowel disease." That is why new abdominal pain in a stimulant user should raise ischaemic bowel, and why a young patient with chest pain and a stimulant history gets a real cardiac work-up.

Two management rules follow from the mechanism and both contradict what an untrained hand would do. First: the hyperthermia is muscular, not hypothalamic. "Antipyretics are not used because the increased body temperature is caused by muscular activity, not an alteration in the hypothalamic temperature set point" — cooling is achieved through "sedation, fluid resuscitation, external cooling blankets, or evaporative cooling techniques." Second: do not use physical restraints. "Physical restraints should be avoided because clients who physically struggle against restraints undergo isometric muscle contractions that are associated with lactic acidosis, hyperthermia, sudden cardiac collapse, and death." Both rules point the same way — sedate the patient, because sedation lowers the temperature, the blood pressure and the heart rate at the same time.

The stimulant chain. Sympathetic outflow and muscular hyperactivity produce the heat, so sedation is the treatment that fixes several problems at once — while restraints and antipyretics each make one of them worse.

04 The four touchpoints — and the tolerance rule that outranks them

Most overdose deaths had a moment when someone could have intervened. Surveillance data relayed by the nursing text puts it plainly: "nearly 85% of overdose deaths involve illicitly manufactured fentanyl, heroin, cocaine, or methamphetamine," and opportunities to link people to care "have been identified for more than three in five people who died from drug overdose." The four touchpoints: a bystander was present in nearly 40% of opioid and stimulant overdose deaths; about 10% had been recently released from an institution such as jail, prison, inpatient rehabilitation or a psychiatric hospital; about 10% had a previous overdose; 25% had a documented mental health diagnosis; and nearly 20% had previously been treated for substance use.

The institutional-release figure comes with the reason attached, and it is the most important sentence on this page. Risk increased in that group "because they were unaware of decreased tolerance to the drug due to abstinence from it while in the institution." The same rule is stated from the treatment side: "because withdrawal management reduces acquired tolerance, those who attempt to reuse their former substance in the same amount or frequency may overdose, especially those with opioid use disorders," and "patients are at the highest risk for opioid-related death in the first 4 weeks of OUD treatment and for 4 weeks after treatment ends," with the peak "the period between detoxification and the start of maintenance therapy."

Which is why the last section of this page is about what detoxification is not. "Medically supervised opioid withdrawal, also known as detoxification, involves administering medication to reduce the severity of withdrawal symptoms… However, supervised withdrawal alone does NOT generally result in sustained abstinence from opioids, nor does it address reasons the client became dependent on opioids." It is "considered stabilization — a first step toward recovery, similar to the acute management of a diabetic coma as a first step toward managing the underlying illness of diabetes." And the drop-off is measured: "half to three quarters of individuals with substance use disorders who receive withdrawal management services do not enter treatment. One of the most serious consequences when individuals do not begin continuing care after withdrawal management is overdose."

Why the highest-risk moment is the one that looks like progress. Every period of enforced or achieved abstinence lowers tolerance without lowering the remembered dose, and detoxification without linked treatment is the commonest route to that trap.

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

Opioid use disorder crosses every demographic — it "occurs in individuals from all educational and socioeconomic backgrounds" Chronic opioid therapy — "up to 50% of patients on chronic opioid therapy meet the criteria for opioid use disorder"; the prescribing lever is the CDC caution against escalating beyond 50 morphine milligram equivalents per day modifiable Family history — first-degree relatives with a substance use disorder — and a deficiency in neurotransmitters such as dopamine Untreated depression, post-traumatic stress disorder, anxiety or childhood trauma — named individual risk factors, and a documented mental health diagnosis was present in 25% of overdose deaths modifiable Environmental exposure — peer use of opioids, or exposure to opioid analgesics after a previous injury modifiable A recent period of enforced abstinence — jail, prison, inpatient rehabilitation, a psychiatric hospital or completed detoxification, because tolerance falls while the remembered dose does not modifiable A previous overdose — present in about 10% of overdose deaths Injection as a route — hepatitis A, B or C is positive in approximately 80% to 90% of injection opioid users, HIV positivity has been reported as high as 60% in some areas, and tetanus, botulism and tuberculosis are named complications modifiable Polysubstance use — and the combination the CDC guideline singles out is sedatives with opioids: "use particular caution when prescribing benzodiazepines or other sedating medications with opioid pain medication" modifiable Sex and age patterns — men are more likely to use and become dependent on opioids and account for most overdoses, while women are prescribed opioids for analgesia more often; opioid-related deaths peak between 40 and 50, heroin overdoses between 20 and 30 Stressful events, loss of economic stability, and relationship problems — the named relapse triggers, since "the vulnerability to relapse occurs throughout a patient’s lifetime" modifiable Barriers to care — not knowing where to go (12.6%), no program offering the desired treatment (11.0%), and no transportation or inconvenient hours (11.8%) modifiable

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

The opioid triad — pinpoint pupils, slow shallow breathing, and an unrousable patient Report immediately
Why: The sourced signs are "unconsciousness or inability to awaken"; "pinpoint pupils"; "slow, shallow breathing; breathing difficulty manifested by choking sounds or a gurgling/snoring noise from a person who cannot be awakened; or respiratory arrest"; and "fingernails or lips turning blue or purple." The pupil earns its place diagnostically: "the presence of miosis in a prehospital patient with altered mental status is highly indicative of responsiveness to naloxone."
Respiratory depression — the one sign that triggers naloxone Report immediately
Why: Naloxone is indicated "specifically to reverse respiratory depression from opioid use," and should be given "to anyone suspected of an opioid overdose when there is evidence of significant respiratory depression or CNS depression." This is the finding that decides the drug, not the level of consciousness alone and not the story.
Dilated pupils with tachycardia, hypertension, diaphoresis and agitation Report immediately
Why: The stimulant (amphetamine) toxicity picture: tachycardia and hypertension, agitation severe enough to endanger staff and the patient, impulsivity and aggression, psychosis, seizures, hyperthermia, and weight loss, dehydration and insomnia; stimulant intoxication also dilates the pupils (StatPearls). The contrast an exam builds on: pupils DILATE with stimulants and CONSTRICT with opioids.
Severe agitation that becomes violent without provocation Report immediately
Why: The sourced warning is explicit and is a staff-safety instruction as much as a clinical one: "it is important for nurses to be aware that individuals with acute stimulant intoxication may, without provocation, develop severe agitation with extreme violence and place themselves, family members, medical staff, and other clients at risk of major injury." Patients may be "highly agitated, even to the point of risking the safety of healthcare staff and themselves."
Hyperthermia in a stimulant-intoxicated patient Report immediately
Why: Generated by muscular activity, not a shifted hypothalamic set point — which is why antipyretics fail and why cooling has to be physical. The sourced urgency thresholds are a body temperature over 41 °C, and "external cooling therapies should be rapidly administered when patients present with temperatures exceeding 107 °F." Untreated it runs to rhabdomyolysis, arrhythmia and cardiovascular collapse.
Chest pain or dyspnea after cocaine or amphetamine Report immediately
Why: On the sourced cocaine presentation list alongside epistaxis, headache, paranoia, neurological deficits, hyperthermia, vascular spasm with loss of distal pulses, extreme diaphoresis and excited delirium. The workup named is an electrocardiogram, chest x-ray and troponin "to assess the presence of coronary ischemia, including myocardial infarction and aortic dissection," plus head computed tomography for haemorrhagic stroke.
Abdominal pain in a patient using stimulants Report immediately
Why: Read it through the vascular mechanism this page has already drawn, not as a gastrointestinal upset. Stimulants "cause NECROTIZING VASCULITIS of small- and medium-sized blood vessels, which can yield a myriad of END-ORGAN COMPLICATIONS (strokes and neurodegenerative diseases, coronary artery disease, ISCHEMIC BOWEL DISEASE)." The same process that causes the stroke and the myocardial infarction on this page can infarct gut, which is why new abdominal pain in this patient is not treated symptomatically and sent home.
Opioid withdrawal — lacrimation, rhinorrhea, gooseflesh, myalgia, diarrhea, vomiting, yawning and dilated pupils Hold & notify
Why: The sourced list adds photophobia, insomnia, and autonomic hyperactivity with tachypnea, hyperreflexia, tachycardia, sweating, hypertension and hyperthermia. Note the pupils: large in withdrawal, pinpoint in overdose — the same patient, two days apart, looks opposite. Timing follows the drug’s half-life: heroin withdrawal begins in as little as five hours, methadone withdrawal 2 to 3 days after the last dose, and duration varies from days to weeks.
Vomiting, diarrhea and sweating together in opioid withdrawal Hold & notify
Why: This is the sourced danger of opioid withdrawal, and it is a volume problem. "Clients who have associated diarrhea, vomiting, or sweating should be monitored for dehydration and have fluid levels maintained with oral and/or intravenous fluids." Note that the dedicated chapter opens by calling opioid withdrawal syndrome "a life-threatening condition," so the familiar reassurance that it is merely unpleasant is not written on this page.
Benzodiazepine withdrawal — tremor and rebound anxiety escalating to hallucinations, agitation and seizures Report immediately
Why: The sourced escalation: initial "tremors, anxiety, restlessness, and general malaise, often resembling rebound anxiety," then "perceptual disturbances such as visual or auditory hallucinations, intense agitation, and depersonalization," sometimes psychosis with paranoid delusions. "Of particular concern is the risk of seizures, which may occur within one to five days of abrupt cessation or rapid tapering," with autonomic instability. GABAergic withdrawal is the dangerous kind, and the alcohol page documents the same picture.
Confusion, agitation or combativeness after naloxone Hold & notify
Why: Precipitated withdrawal, and it is expected rather than a complication of care. "The most common adverse effects associated with naloxone occur after acute withdrawal from opioids. These include anxiety, aggression, nausea, vomiting, diarrhea, abdominal pain, and rhinorrhea." The nursing response is scripted: "withdrawal triggered by naloxone can feel unpleasant; some people may awaken confused, agitated, or aggressive. Provide safety, reassurance, and explain what is happening."
Persistent hypoxia after the respiratory depression has resolved Report immediately
Why: The rare naloxone complication worth recognising: it "can precipitate noncardiogenic pulmonary edema," estimated at "between 0.2% and 3.6% of patients who have received naloxone and are transported to the emergency department," and "symptoms include persistent hypoxia despite the resolution of respiratory depression." A patient who is breathing adequately but still desaturating has a second problem.
Long-term methamphetamine signs — extreme weight loss, severe dental problems, skin sores from scratching, involuntary movements late Expected
Why: A recognition finding, not an act-now one — these are the marks of prolonged use rather than an event to escalate. The sourced list also includes "anxiety, memory loss, and violent behavior," and the itching is described as intense enough to cause the sores. Amphetamine toxicity presentations include "anorexia, dehydration, weight loss, and insomnia," and the examination should look for "skin ulcerations or abscesses" as well as hyperthermia and end-organ damage.
Nasal septal perforation late Hold & notify
Why: A route-specific harm that is visible on examination and tells you how the drug is being taken. "Users who SNORT heroin or other opioids develop irritation of the nasal mucosa, which can sometimes lead to PERFORATION OF THE NASAL SEPTUM." Finding it changes the conversation from whether there is use to which route and how long — and it is worth asking about the others in the same breath, because the route determines which complications to screen for.
Sudden collapse in a young person using inhalants Report immediately
Why: Sourced as its own entity: acute inhalant intoxication "can cause life-threatening seizures and coma," and sniffing these products "can cause the heart to stop within minutes. This condition, known as sudden sniffing death, can happen to otherwise healthy young people the first time they use." Inhalant use "was highest among adolescents aged 12 to 17."

Diagnostics

Test In this disorder Normal
Initial evaluation for opioid use disorder "If the patient uses intravenous drugs, tests should be ordered to screen for HIV and hepatitis B and C." That is not defensive medicine — hepatitis A, B or C is positive in approximately 80% to 90% of injection opioid users, and HIV positivity has been reported as high as 60% in some regions and as low as 10% in others A full social and mental health history, including "history of injuries, trauma, previous surgeries, and hospitalization… to identify gateways for opioid use." Urine drug screening for opioids should be performed BEFORE starting treatment and regularly at subsequent visits —
Urine toxicology — and the three gaps in it Gap one: "methadone, buprenorphine, and LAAM will NOT be detected in positive urine opiate tests, and they must be specifically tested." Gap two, on the stimulant side: "ingestion of some amphetamines… will not reliably result in a positive test," while false positives arise from "pseudoephedrine, mebeverine, metoprolol, tetracaine, dimethylamylamine, aripiprazole, and ranitidine" — so "clinicians should not rely on drug metabolite testing alone." Gap three: there is no diagnostic test for opioid withdrawal at all; toxicology is run "to rule out withdrawal from any other drugs" Positive for "most opioids such as morphine, heroin, codeine, oxycodone, and propoxyphene for 12 to 36 hours after use" —
Baseline laboratory work For suspected stimulant toxicity the panel widens with a purpose attached to each test: a basic metabolic panel for dehydration and hyponatremia; ECG, chest x-ray and troponin for coronary ischemia, myocardial infarction and aortic dissection; head CT for haemorrhagic stroke causing neurologic deficits; and serum creatine kinase and lactic acid to identify "muscle damage and tissue ischemia related to tonic-clonic seizures, myoclonus, or hyperthermia" ECG, complete blood count, blood alcohol level and basic metabolic panel —
COWS — the Clinical Opiate Withdrawal Scale The score is not paperwork — it is the gate on the first buprenorphine dose, which is withheld until the score exceeds 10. COWS exists precisely because buprenorphine "can precipitate withdrawal in opioid-dependent patients who are NOT experiencing any withdrawal symptoms," and it is administered serially "to track changes in the severity of withdrawal symptoms over time or in response to treatment." The per-item scoring is not stated here because the two fetched sources give arithmetically incompatible descriptions of it 11 signs and symptoms of opioid withdrawal, total score 0 to 47, banded as mild 5–12 · moderate 13–24 · moderately severe 25–36 · severe above 37 COWS via StatPearls, citing the instrument’s original publication —
CIWA-Ar — named here only for the pairing Learn the pairing: CIWA-Ar for alcohol, COWS for opioids. The Alcohol Withdrawal page owns CIWA-Ar in full, including its severity bands and the caution that it is a severity tool rather than a diagnostic one — this page deliberately does not restate different numbers The alcohol instrument, described as "the most widely used scale to determine the need for medically supervised withdrawal management" —
Prescription drug monitoring programs The threshold that pairs with it, in the guideline’s own words: "If a patient’s opioid dosage for all sources of opioids combined reaches or exceeds 50 MME/day, clinicians should implement additional precautions, including increased frequency of follow-up, and offer naloxone and overdose prevention education to both the patient and the patient’s household members." CDC 2022 also records why the number sits there — increases above 50 MME/day "are unlikely to provide substantially improved pain control for most patients while overdose risk increases." And the co-prescribing caution belongs beside it: "use particular caution when prescribing benzodiazepines or other sedating medications with opioid pain medication… and check the prescription drug monitoring program (PDMP) database" An electronic system tracking controlled-substance prescriptions. "PDMPs play a crucial role in identifying patients who may be at risk of overdose," and providers "should routinely review PDMP data," including "when initiating the use of opioids to alleviate acute, subacute, or chronic pain" CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 —
Discharge criteria after a naloxone reversal Waking up is not on that list. Naloxone’s half-life is 30 to 80 minutes and is shorter than methadone, fentanyl and buprenorphine, so re-sedation is expected rather than surprising. Monitoring windows differ by source and both should be named: at least 4 hours from the last naloxone dose per the nursing text, and 6 to 12 hours per StatPearls, with longer monitoring for long-acting opioids For respiratory depression fully reversed with 0.4 to 2 mg of naloxone, observe for 2 to 4 hours, and require all of: Glasgow coma scale 15 · no further naloxone needed · oxygen saturation at least 92% on room air · respiratory rate at least 10 · pulse between 50 and 120 · blood pressure between 110/90 and 140/90 mm Hg · tolerating clear liquids and ambulating with no withdrawal symptoms · someone to drive them home and monitor them for the next 12 to 24 hours —

Complications

Warning: Overdose after a period of abstinence Report immediately
"Because withdrawal management reduces acquired tolerance, those who attempt to reuse their former substance in the same amount or frequency may overdose." The highest-risk periods are "the first 4 weeks of OUD treatment and… 4 weeks after treatment ends," with the peak being "the period between detoxification and the start of maintenance therapy."
The population most exposed to this is the one least warned about it. About 10% of overdose deaths involved someone recently released from jail, prison, inpatient rehabilitation or a psychiatric hospital, and the sourced reason is that they "were unaware of decreased tolerance to the drug due to abstinence while in the institution." A medical-surgical admission for something unrelated does the same thing. Tolerance-loss teaching belongs in every discharge from every setting where a patient has been abstinent, not just from addiction services.
Warning: Re-sedation after naloxone Report immediately
Naloxone’s half-life is 30 to 80 minutes — shorter than the opioids it reverses. "All patients who have responded to naloxone should be continuously monitored for 6 to 12 hours since some opioids (methadone, fentanyl, buprenorphine) have a much longer half-life than naloxone."
The patient-facing version matters as much as the clinical one: "it is essential to get the person to an emergency department… even if the person revives after the initial dose of naloxone and seems to feel better," and patients themselves "should be educated that once the pharmacological effects of naloxone have worn off, there is a possibility of respiratory depression." Overdoses involving potent or large quantities of opioids "may require additional doses of naloxone," and long-acting or potent opioids may need "additional intravenous bolus doses or an infusion." If repeated doses produce no response, "providers must consider other causes of unconsciousness."
Warning: Stimulant end-organ damage Report immediately
Rhabdomyolysis, acute kidney injury and multi-organ failure may develop, requiring "supportive care such as IV hydration or renal replacement therapy," with "continuous cardiac monitoring… critical due to the high risk of arrhythmias and myocardial infarction."
Two mechanisms run in parallel. The acute one is muscular: hyperactivity generates heat and breaks down muscle, producing lactic acidosis, hyperthermia and collapse. The chronic one is vascular: necrotizing vasculitis of small- and medium-sized vessels producing "strokes and neurodegenerative diseases, coronary artery disease, ischemic bowel disease," plus corneal ulceration and vision loss on the cocaine list. There is no antidote — "treating amphetamine toxicity is supportive… treatment should focus on symptom and complication management."
Warning: Infection from injection Hold & notify
Screening tests for hepatitis A, B and C are positive in approximately 80% to 90% of injection opioid users; HIV positivity has been reported "as high as 60%" in some regions. Tetanus, botulism and tuberculosis are also named, with tuberculosis "a serious problem… especially heroin drug users."
This is why the screening instruction is unconditional: "if the patient uses intravenous drugs, tests should be ordered to screen for HIV and hepatitis B and C." Naloxone recipients "often present with underlying chronic liver diseases such as alcoholic liver disease, hepatitis B, or hepatitis C." Note what is not on this page: no fetched source recommends hepatitis B vaccination for people who inject drugs, so the page teaches screening and links the hepatitis and HIV pages rather than inventing an immunisation recommendation.
Caution: The treatment gap
"Half to three quarters of individuals with substance use disorders who receive withdrawal management services do not enter treatment. One of the most serious consequences when individuals do not begin continuing care after withdrawal management is overdose."
The sourced barriers are practical, not motivational: not knowing where to go (12.6%), no program offering the treatment wanted (11.0%), and no transportation, programs too far away, or inconvenient hours (11.8%). The sourced nursing response is equally concrete — "nurses can use motivational interviewing strategies to explore clients’ reasons for not seeking treatment and address their perceived barriers." Against that gap, what treatment achieves is measurable: methadone treatment is associated with a 50% reduction in all-cause mortality and a 50% reduction in the incidence of hepatitis C, and "almost half of patients can maintain abstinence from additional opioids while receiving replacement therapy."

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Opioid Analgesics High-alert
Nervous · morphine

This class is on the page as the mechanism of harm, and as the thing being reversed. The disorder-side teaching is the chain: mu-receptor agonism produces analgesia and euphoria, but also tolerance, physical dependence, withdrawal on cessation, and the dose-dependent respiratory depression that is the actual mechanism of death. The numbers that make it a prescribing problem rather than only a street problem: up to 50% of patients on chronic opioid therapy meet the criteria for opioid use disorder, and in the United States, opioids have killed more people than any other drug in history. The prescribing lever, per CDC 2022 guidance as reported by StatPearls: exercise caution before escalating beyond 50 morphine milligram equivalents per day, because higher doses "typically fail to significantly enhance pain relief for most patients while simultaneously increasing the risk of overdose" — and at that threshold, provide naloxone and overdose prevention education to the patient and their household members, with more frequent follow-up. The modern context is contamination: there are "two types of fentanyl — pharmaceutical fentanyl prescribed for severe pain, and illicitly manufactured fentanyl," and "most recent cases of fentanyl-related overdose are associated with illicitly manufactured fentanyl that is added to other street drugs that make them more powerful, more addictive, and more dangerous." Carfentanil is the one potency figure this page can source: "approximately 10,000 times more potent than morphine and 100 times more potent than fentanyl… a miniscule amount of powder containing two milligrams can be lethal," and it "can be accidentally absorbed through the skin or inhaled by unsuspecting parties," so first responders must follow safety protocols. The class page owns equianalgesic dosing, individual agents and adverse-effect profiles. What this page adds is why the legitimate analgesic becomes the disorder, and the one non-opioid alternative the source names — "nonopioid drugs and physical therapy can provide a long-term solution to pain management instead of relying on the use of opioids."
CNS Stimulants (ADHD)
Nervous · methylphenidate

The disorder-side role here is toxicity and its management, and the management is counter-intuitive twice over. Sedation is first-line, and four separate sources say so: "intravenous benzodiazepines are administered immediately for chemical sedation of severely agitated individuals" and "remain the first-line treatment to manage agitation and prevent seizures"; cardiovascular toxicity and agitation are "best treated first-line with benzodiazepines to decrease CNS sympathetic outflow"; "diazepam is an ideal choice if intravenous access is available; otherwise, intramuscular lorazepam or midazolam is appropriate"; and hyperadrenergic symptoms should be managed with benzodiazepines "titrated to effect and repeated as necessary." Titrating to effect means watching the airway while you do it, because the doses that settle a hyperadrenergic patient are not small. Sedation is efficient because it treats several problems at once — "hypertension related to amphetamine toxicity may abate with agitation treatment." On beta-blockers, teach the disagreement rather than the mnemonic. The amphetamine chapter says they "should not be used as SOLE antihypertensive therapies as their use may lead to unopposed alpha-adrenergic tone," preferring nitroglycerin and nicardipine. The methamphetamine chapter names labetalol or carvedilol — combined alpha-1 and beta antagonists — as adjuncts when agitation persists despite adequate benzodiazepines, with alpha-2 agonists dexmedetomidine or clonidine as alternatives. The defensible teaching: sedate first; never a beta-blocker as sole therapy; if one is used, a combined alpha-1/beta agent is the sourced choice. Two other agent notes: non-dihydropyridine calcium channel blockers (diltiazem, verapamil) reliably reduce hypertension but not tachycardia, and dihydropyridines such as nifedipine should be AVOIDED because reflex tachycardia may occur; and haloperidol for stimulant delirium "may cause harm" — it can lower the seizure threshold, cause extrapyramidal effects, increase heat production by altering thermoregulatory function, and prolong the QTc.
Benzodiazepines
Nervous · diazepam

Double-edged, and both edges are sourced. The positive role is first-line sedation in stimulant toxicity — for agitation, for seizure prevention, and as the intervention that lowers temperature, blood pressure and heart rate together. The second positive role is substitution in sedative withdrawal: "substituting the short-acting benzodiazepine the individual has been using with a long-acting one, such as diazepam or clonazepam, which provides more stable blood levels and reduces the intensity of withdrawal symptoms. The medication is then gradually tapered… The tapering process can last several weeks to several months." The negative role is a co-prescribing rule that exists because of a boxed warning: "use of benzodiazepines and zolpidem is NOT recommended for clients receiving methadone or buprenorphine therapy unless they are under close medical supervision due to the risk of oversedation." The same principle governs methadone generally — it "is medically safe, provided there is no concomitant use of other prescription or illicit drugs." And the withdrawal these drugs produce is the dangerous kind: tremor and rebound anxiety escalating through hallucinations and agitation to seizures within one to five days of abrupt cessation or rapid tapering, with autonomic instability. That is the sourced basis for the contrast this page teaches — GABAergic withdrawal, whether from alcohol or benzodiazepines, has documented seizure and delirium risk, and the Alcohol Withdrawal page carries the parallel picture in full.
Antiemetics
Digestive / GI · ondansetron

Not comfort care — volume protection. The sourced symptomatic regimen for opioid withdrawal is specific by symptom: "nausea/vomiting: ondansetron, prochlorperazine, and promethazine," alongside "loperamide for diarrhea… and ibuprofen for myalgia." The disorder-side rationale is what makes this a nursing priority rather than a convenience: "clients who have associated diarrhea, vomiting, or sweating should be monitored for dehydration and have fluid levels maintained with oral and/or intravenous fluids." Controlling the vomiting is how the nurse prevents the volume loss, and volume loss is one of the two sourced hazards of opioid withdrawal — the other being the collapse of tolerance that follows it. The environment does some of this work too: "a calm, quiet environment with supportive and reassuring staff is instrumental for helping clients overcome most symptoms of acute opioid withdrawal and can decrease the need for pharmacologic interventions," with warm baths, rehydration and gentle stretching named for muscle aches and cramps. The class page owns the antiemetic pharmacology; this page teaches which symptom gets which agent and why the vomiting matters.

Beyond medications

  • NALOXONE — what it is, every route, and the dosing rule that depends on dependence. It is "usually administered intravenously. However, if IV access can’t be achieved, it can also be administered via an intraosseous, subcutaneous, intramuscular, or intranasal route," and intravenously it "completely reverses the effects of opioids within a few minutes." Formulations include injectable 0.4 mg/mL and 1 mg/mL solutions and a 5 mg/0.5 mL high-dose prefilled syringe, with intranasal actuations of 3 mg, 4 mg and 8 mg. The critical rule: "the dose is titrated to increase the patient’s respiratory drive and allow for adequate spontaneous respiration and oxygenation, BUT NOT FULL REVERSAL. This can result in withdrawal and include combative or aggressive behavior." A small initial IV dose of 0.04 to 0.1 mg is recommended in a known opioid-dependent patient; 0.4 mg in someone without known dependency. Repeat every 2 to 3 minutes in alternating nostrils for intranasal use, or every 2 to 5 minutes for longer-acting agents, with an IV drip in some cases. The goal is adequate breathing, not complete arousal.
  • THE FIVE OVERDOSE RESPONSE STEPS, in order. (1) Evaluate and get help — "try to stimulate the person by calling their name or vigorously grinding one’s knuckles into their sternum. If the person does not respond, call 911." (2) Rescue breathing, compressions and oxygen — "be sure the person’s airway is clear. Place one hand on the person’s chin, tilt the head back, and pinch the nose closed… give two slow breaths. Watch for the person’s chest (but not the stomach) to rise. Follow up with one breath every five seconds. If the individual becomes pulseless, provide cardiopulmonary resuscitation." (3) Give the first naloxone dose. (4) Give a second dose if there is no response in 2 to 3 minutes. (5) Monitor the response, including for re-sedation. The American Heart Association position relayed alongside it: "laypersons and others who cannot reliably confirm the presence of a pulse should initiate cardiopulmonary resuscitation in any individual who is unconscious and not breathing normally, with the additional recommendation to administer naloxone if opioid overdose is suspected."
  • Who gets naloxone, and who gets missed. "Clinicians should offer naloxone to ALL patients with OUD," and it "is reasonable to prescribe naloxone to any patient with OUD," with prescriptions "also considered for a more general population of patients taking chronic opioids." More than a dozen states have passed good samaritan laws permitting prescription to family members or caregivers. The nasal spray exists specifically "to permit medically untrained individuals to safely administer naloxone," with no concern about venous access, needlestick or sharps disposal — though "the price of this formula is still a major issue." And the equity point is explicitly sourced: "women, older adults, and those without obvious signs of opioid use disorder are undertreated with naloxone and, as a result, have a higher death rate. Therefore, naloxone should be considered for women and the elderly who are found unresponsive." Storage, per SAMHSA as relayed: room temperature in a protective outer case, replaced on expiry and if exposed below 3.8 °C or above 40 °C.
  • MEDICATIONS FOR OPIOID USE DISORDER — plain-text notes, and the timing rules are the exam. Buprenorphine is a partial mu agonist, and "it is crucial to ensure that the patient is in opioid withdrawal BEFORE initiation… to avoid precipitated withdrawal." The operational gate: "the client must be in a state of mild to moderate withdrawal before receiving their first dose — that is, have a COWS score greater than 10. The first dose is typically 2 to 4 mg sublingually." The time-based version: 12 to 18 hours after a short-acting agonist, 24 to 48 hours after a long-acting one. Naloxone is added to the combination product because it "is not absorbed orally and only exerts its action when injected," deterring misuse. Methadone is a full mu agonist, dispensed in the US "only for specially monitored clinics," offering "reduced euphoric effects, decreased narcotic cravings, and reduced transmission of infectious diseases" — and, crucially, it "does not induce withdrawal symptoms when administered to a client with opioid in their system because it has an additive effect on opioids that are already present." Watch its long half-life. Naltrexone is an antagonist that "may only be initiated when the patient is free of physiological opioid dependence, and at least seven days without acute withdrawal symptoms are required"; the intramuscular form may be more effective and is FDA-approved for opioid dependence, with monthly dosing aiding compliance.
  • What the medications achieve, and how long they run. "Almost half of the patients can maintain abstinence from additional opioids while receiving replacement therapy," and "methadone treatment is associated with a 50% reduction in all-cause mortality, as well as a 50% reduction in the incidence of hepatitis C," plus decreased drug-related crime and improved retention. There is no winner between methadone and buprenorphine — "no consensus among experts… the agent use should be based on patient-specific factors," though methadone "may increase patient retention" and "may treat withdrawal symptoms and cravings better than buprenorphine for patients who use fentanyl." Duration is genuinely contested: some clinicians stop after a year, others "suggest that treatment should be lifelong due to the risk of relapse and overdose death after patients stop." Access changed in December 2022: the MAT Act eliminated the DATA-Waiver (X-Waiver) program, so "all DEA-registered practitioners with Schedule III prescribing authority may now prescribe buprenorphine for OUD," with no patient limits and no tracking, subject to state law. Adjuncts: clonidine may abate withdrawal while the methadone or buprenorphine dose is adjusted, tizanidine helps anxiety and muscle pain, bupropion targets anxiety symptoms, and lofexidine — FDA-approved in May 2018 as "the first non-opioid for managing opioid withdrawal syndrome" — is an alpha-2 agonist usable up to 14 days that works by reducing sympathetic tone and norepinephrine release.
  • WITHDRAWAL MANAGEMENT IS NOT TREATMENT — and the sources say so twice. "Supervised withdrawal alone does NOT generally result in sustained abstinence from opioids, nor does it address reasons the client became dependent on opioids," and "by itself, it is not an effective treatment for any substance use disorder. It is considered stabilization… a first step toward recovery, similar to the acute management of a diabetic coma as a first step toward managing the underlying illness of diabetes." The four sourced reasons patients enter it: getting clean and staying clean; treating withdrawal in a patient hospitalised for something else who now lacks access to the substance; beginning treatment and transitioning to medication-assisted treatment; and establishing abstinence required by a setting such as incarceration, probation or a drug-free residence. The second of those is the one a medical-surgical nurse meets most often.
  • Psychosocial treatment and harm reduction. Rehabilitation "begins with a cognitive behavioral approach similar to that used in the treatment of other chronic conditions," aiming "to minimize drug relapses," with patients "encouraged to participate in self-help programs such as Narcotics Anonymous"; group therapy "helps maintain self-control and restraint" and "is also cost-effective compared to individualized therapy." CBT "is most effective if combined with medications." Harm reduction — exactly the four strategies the sources name: "outreach and education programs, needle/syringe exchange programs, overdose prevention education, and improving public access to naloxone," designed for people who are "not yet ready to participate in treatment," to reduce overdose and infection transmission and to encourage individuals to seek treatment.
  • Stimulant overdose care beyond sedation. Immediate goals are "sedation, cardiovascular stabilization, airway protection, and cooling," escalating in severe cases to "endotracheal intubation, mechanical ventilation, and advanced cardiac life support," with "continuous cardiac monitoring… critical due to the high risk of arrhythmias and myocardial infarction," and supportive care including IV hydration or renal replacement therapy for rhabdomyolysis and acute kidney injury. Cooling is physical, not pharmacological: "aggressive cooling is achieved through sedation, fluid resuscitation, external cooling blankets, or evaporative cooling techniques," with rapid cooling above a body temperature of 41 °C, or temperatures exceeding 107 °F in the amphetamine source. There is no antidote.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment & monitoring
Check the pupils, and let them tell you which toxidrome you are looking at.
Why: Pinpoint pupils with slow shallow breathing and an unrousable patient is the opioid picture, and "the presence of miosis in a prehospital patient with altered mental status is highly indicative of responsiveness to naloxone." Dilated pupils with tachycardia, hypertension, sweating and agitation is the stimulant picture. And the same opioid patient two days later, in withdrawal, will have dilated pupils — which is why the pupil is read alongside the respiratory rate, not alone.
Screen every patient who injects for HIV and hepatitis B and C, and order the urine drug screen before starting treatment, not after.
Why: The screening instruction is unconditional in the source, and the reason is the prevalence: hepatitis A, B or C is positive in approximately 80% to 90% of injection opioid users. Urine screening "should be performed before starting treatment for OUD and regularly with subsequent visits to evaluate compliance with treatment and abstinence." Know its gaps — methadone and buprenorphine are not detected by an opiate screen and must be tested for specifically.
Score COWS serially, and treat a score above 10 as the gate on the first buprenorphine dose.
Why: COWS is "serially administered to track changes in the severity of withdrawal symptoms over time or in response to treatment," and it exists because buprenorphine "can precipitate withdrawal in opioid-dependent patients who are not experiencing any withdrawal symptoms." The bands are mild 5–12, moderate 13–24, moderately severe 25–36 and severe above 37, out of 47. The clinically load-bearing number is 10 — below it, giving buprenorphine causes the problem it is meant to treat.
Monitor for dehydration in any patient with opioid withdrawal who is vomiting, having diarrhea or sweating.
Why: These patients "should be monitored for dehydration and have fluid levels maintained with oral and/or intravenous fluids." This is the sourced hazard of opioid withdrawal, alongside the tolerance loss that follows it — and it is the reason antiemetics and antidiarrheals here are volume protection rather than comfort measures.
After a naloxone reversal, monitor for re-sedation and do not use wakefulness as a discharge criterion.
Why: Naloxone’s half-life is 30 to 80 minutes, shorter than methadone, fentanyl and buprenorphine. Monitor at least 4 hours from the last dose per the nursing text, or 6 to 12 hours per StatPearls, and longer for long-acting opioids. Discharge requires the full sourced checklist, including Glasgow coma scale 15, no further naloxone needed, saturation at least 92% on room air, respiratory rate at least 10, and someone to monitor the patient for 12 to 24 hours.
Watch for persistent hypoxia after the breathing has been restored.
Why: Naloxone "can precipitate noncardiogenic pulmonary edema" in an estimated 0.2% to 3.6% of patients who receive it and are transported to the emergency department, and "symptoms include persistent hypoxia despite the resolution of respiratory depression." A patient who is breathing adequately but still desaturating is not simply slow to recover.
Interventions & safety
Titrate naloxone to adequate breathing, not to full arousal — and start small in a known opioid-dependent patient.
Why: "The dose is titrated to increase the patient’s respiratory drive and allow for adequate spontaneous respiration and oxygenation, but not full reversal. This can result in withdrawal and include combative or aggressive behavior." The sourced starting doses are 0.04 to 0.1 mg IV if opioid-dependent and 0.4 mg if not. The nursing text states the same goal: "restore adequate spontaneous breathing but not necessarily achieve complete arousal."
Expect precipitated withdrawal after naloxone and manage it with safety, reassurance and explanation rather than surprise.
Why: "Withdrawal triggered by naloxone can feel unpleasant; some people may awaken confused, agitated, or aggressive. Provide safety, reassurance, and explain what is happening." The common adverse effects are exactly the withdrawal syndrome — anxiety, aggression, nausea, vomiting, diarrhea, abdominal pain and rhinorrhea. A patient who wakes up furious is having a predicted drug effect, not a behavioural problem.
Never physically restrain an agitated stimulant-intoxicated patient.
Why: The mechanism is given with the rule: "physical restraints should be avoided because clients who physically struggle against restraints undergo isometric muscle contractions that are associated with lactic acidosis, hyperthermia, sudden cardiac collapse, and death." The alternative is chemical sedation with parenteral benzodiazepines, which is first-line anyway. Note this rule does not generalise — in the schizophrenia and bipolar settings seclusion and restraint remain a last resort under ANA guidance; in stimulant intoxication specifically the sourced position is avoidance.
Never give an antipyretic for stimulant hyperthermia.
Why: "Antipyretics are not used because the increased body temperature is caused by muscular activity, not an alteration in the hypothalamic temperature set point," and again, "antipyretics are ineffective and not indicated." What works is sedation, intravenous fluids, external cooling blankets and evaporative cooling, applied rapidly above a body temperature of 41 °C. Reaching for acetaminophen wastes the minutes that matter.
Plan for staff safety before approaching an acutely stimulant-intoxicated patient.
Why: The warning is explicit: these patients "may, without provocation, develop severe agitation with extreme violence and place themselves, family members, medical staff, and other clients at risk of major injury," and may be agitated "to the point of risking the safety of healthcare staff and themselves." Sedation is the intervention; adequate staffing and preparation are the precondition for delivering it.
Use a calm, quiet environment with reassuring staff in opioid withdrawal, and add warm baths, rehydration and gentle stretching.
Why: It is a sourced intervention with a measurable aim: such an environment "is instrumental for helping clients overcome most symptoms of acute opioid withdrawal and can decrease the need for pharmacologic interventions." Warm baths, rehydration and gentle stretching "are also helpful for relieving muscle aches and cramps." The alcohol page records the identical principle, which is worth knowing because the two situations look very different and call for the same room.
Question a benzodiazepine or zolpidem order in a patient on methadone or buprenorphine.
Why: The sourced rule: their use "is not recommended for clients receiving methadone or buprenorphine therapy unless they are under close medical supervision due to the risk of oversedation." The same principle applies to methadone generally — it is medically safe "provided there is no concomitant use of other prescription or illicit drugs." This is the bedside expression of the boxed warning on combining benzodiazepines with opioids.
Patient & family teaching
Teach the tolerance rule at every discharge, including from admissions that had nothing to do with substance use.
Why: Any period of abstinence — incarceration, rehabilitation, a psychiatric admission, a completed detoxification, or a week in hospital for something else — lowers tolerance while leaving the remembered dose intact. About 10% of overdose deaths involved someone recently released from an institution, and the sourced reason is that they were "unaware of decreased tolerance to the drug due to abstinence." The highest-risk periods are the first 4 weeks of treatment and the 4 weeks after it ends.
Send naloxone home with the patient AND teach the household, not just the patient.
Why: CDC 2022 makes offering naloxone a category A recommendation — "clinicians should work with patients to incorporate into the management plan strategies to mitigate risk, including offering naloxone" — and says who it is for: "offer naloxone, particularly if the patient or a household member has risk factors for opioid overdose." At or above 50 MME/day the guideline calls for naloxone and overdose-prevention education "to both the patient and the patient’s household members." It is explicitly a bystander drug: administration "by laypersons, such as friends, family, and caregivers of persons who experience opioid overdose, can save lives." A bystander was present in nearly 40% of opioid and stimulant overdose deaths — which is the single strongest argument for teaching whoever else is in the house.
Teach the five overdose response steps to the family, in order, including the rescue-breathing rate.
Why: Stimulate and call 911; clear the airway, tilt the head, pinch the nose, give two slow breaths and then one breath every five seconds, starting CPR if the person becomes pulseless; give naloxone; give a second dose if there is no response in 2 to 3 minutes, in the alternate nostril; and monitor. The nasal spray exists precisely so that "medically untrained individuals" can do this.
Teach that re-sedation is expected and that the emergency department visit is not optional.
Why: "It is essential to get the person to an emergency department… even if the person revives after the initial dose of naloxone and seems to feel better," and patients themselves should know that "once the pharmacological effects of naloxone have worn off, there is a possibility of respiratory depression." Naloxone lasts 30 to 80 minutes; the opioid usually lasts longer.
Explain the buprenorphine timing before the patient is in withdrawal, so the wait makes sense.
Why: Buprenorphine can precipitate withdrawal if given too early, so it is withheld until the patient is in mild to moderate withdrawal — COWS above 10, or 12 to 18 hours after a short-acting opioid and 24 to 48 hours after a long-acting one. Told in advance, the delay is a safety measure; discovered at the bedside, it looks like being refused treatment. Methadone behaves oppositely and can be given with opioid still on board.
Frame detoxification as step one, and arrange the link to continuing care before discharge.
Why: "Half to three quarters of individuals… who receive withdrawal management services do not enter treatment," and "one of the most serious consequences when individuals do not begin continuing care after withdrawal management is overdose." The sourced barriers are practical — not knowing where to go, no program offering what they want, transport and hours — and the sourced nursing response is motivational interviewing to explore the reasons and address the perceived barriers.
Offer harm reduction to the patient who is not ready to stop, and mean it.
Why: These strategies exist "to engage people in treatment, as well as address the needs of individuals who are not yet ready to participate in treatment": outreach and education programs, needle and syringe exchange, overdose prevention education, and improving public access to naloxone. They reduce overdose and infection transmission, and they "encourage individuals to seek treatment" — which makes them a route into care rather than an alternative to it.

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    At the scene the triad is complete. Pinpoint pupils, a respiratory rate of 4, and an unrousable patient — with blue lips and nail beds as the late visible sign. Miosis in a patient with altered mental status "is highly indicative of responsiveness to naloxone," and respiratory depression is the specific finding naloxone is indicated for. The second cue set is the history, and it is the one that explains why tonight. He was released from jail eleven days ago and used the amount he used to use. That is the single most lethal combination on this page: tolerance fell during the enforced abstinence while the remembered dose did not. About 10% of overdose deaths involve someone recently released from an institution, for exactly this reason. The third cue is the sister herself — a bystander was present, as in nearly 40% of overdose deaths, and unlike most of them she had naloxone and knew how to use it.

  2. 2
    Analyze cues

    The combativeness is not a behavioural problem, it is a drug effect. "The most common adverse effects associated with naloxone occur after acute withdrawal from opioids," including anxiety and aggression — and full reversal "can result in withdrawal and include combative or aggressive behavior," which is why the dosing goal is adequate breathing rather than complete arousal. The next question is time, not appearance. Naloxone’s half-life is 30 to 80 minutes, shorter than the opioid he took, so re-sedation is expected. He is not ready for discharge because he woke up; discharge requires the full criteria, including a Glasgow coma scale of 15, no further naloxone needed, saturation at least 92% on room air, and someone to monitor him for 12 to 24 hours. Then the day-2 picture is the mirror image of day 0. Lacrimation, rhinorrhea, gooseflesh, myalgia, vomiting, diarrhea, yawning and dilated pupils are opioid withdrawal — and the discriminator from sedative withdrawal is exactly those first three, since "sedative-hypnotic withdrawal symptoms may resemble opioid withdrawal characteristics, but opioid withdrawal is also characterized by lacrimation, rhinorrhea, and pupillary dilation."

  3. 3
    Prioritize

    Day 0, first: airway and breathing, then continued monitoring for re-sedation — not discharge. Second: screening he will not get if he leaves, since he injects — HIV and hepatitis B and C, plus CBC, basic metabolic panel, ECG, blood alcohol and a urine drug screen, remembering that methadone and buprenorphine will not show on an opiate screen. Day 2, first: volume. He is vomiting, having diarrhea and sweating simultaneously, and that combination is the sourced hazard of opioid withdrawal — monitor for dehydration and replace fluids. Second: symptom control that protects the volume — ondansetron for the nausea, loperamide for the diarrhea, ibuprofen for the myalgia — alongside the calm, quiet environment that "can decrease the need for pharmacologic interventions." Third: COWS, scored serially, because it gates the buprenorphine. Fourth, and the one most often skipped: the discharge plan, because withdrawal management alone is stabilisation, not treatment.

  4. 4
    Generate solutions

    Anticipate observation for at least 4 hours from the last naloxone dose per the nursing text, or 6 to 12 hours per StatPearls, with the longer window if a long-acting opioid is suspected. Anticipate that his COWS of 14 is moderate withdrawal and is above the threshold of 10, so buprenorphine 2 to 4 mg sublingually can be started — given yesterday it would have precipitated withdrawal rather than treated it. Know the alternative shapes: methadone could have been given with opioid still on board, because "it has an additive effect on opioids that are already present," but is clinic-dispensed with a long half-life; naltrexone is not an option yet, because it "may only be initiated when the patient is free of physiological opioid dependence, and at least seven days without acute withdrawal symptoms are required." Plan the discharge package: naloxone and overdose-prevention education for him and for his sister; a linked referral for continuing treatment; and the explicit warning that the first 4 weeks of treatment and the 4 weeks after it ends are his highest-risk periods.

  5. 5
    Take action

    On day 0, stay with him through the agitation, keep him safe, and explain what is happening — the sourced instruction is safety, reassurance and explanation, because he is experiencing a withdrawal syndrome that the treatment caused. Escalate with an SBAR: "29-year-old man, found unresponsive with pinpoint pupils and a respiratory rate of 4, reversed with two doses of intranasal naloxone given by a family member. He is now breathing at 16 with a saturation of 96%, but agitated with precipitated withdrawal. He injects heroin and was released from jail eleven days ago, using his pre-incarceration amount — this is a tolerance-loss overdose. I am monitoring for re-sedation because naloxone’s half-life is shorter than the opioid. Requesting HIV and hepatitis B and C screening, and I would like him seen by the addiction team before discharge." Three traps to avoid. Discharging him because he woke up. Reading the agitation as non-cooperation. And giving buprenorphine on day 0 to settle him — it would have precipitated the withdrawal it is meant to relieve.

  6. 6
    Evaluate

    Day 0 success: he stays awake and breathing without further naloxone, meets every discharge criterion rather than just looking better, and has bloods drawn that would never have been taken if he had walked out. Day 2 success: vomiting and diarrhea controlled, volume maintained, COWS trending down after the first buprenorphine dose, and no precipitated withdrawal because the dose was given at a score above 10. Discharge success is the part that decides whether he is here again: naloxone in the house and his sister taught to use it; a linked referral rather than a leaflet, because half to three quarters of people who complete withdrawal management never enter treatment and "one of the most serious consequences… is overdose"; and the tolerance rule said out loud — the amount that was normal before jail is not normal now, and the same is true after every hospital stay. Re-escalation triggers: any drop in respiratory rate or level of consciousness during observation; persistent hypoxia despite adequate breathing, which suggests noncardiogenic pulmonary edema; and signs of volume depletion during withdrawal.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Emergency department, then the medical unit · day 0 to day 2

A 29-year-old man is found unresponsive on the bathroom floor by his sister. He was released from jail eleven days ago. She calls 911, and while waiting she gives him naloxone from a kit she was given when he was discharged. He arrives in the emergency department breathing spontaneously but confused and briefly combative, and is admitted for observation.

At the scene — unrousable to sternal rub · pinpoint pupils · RR 4 with gurgling breathing · lips and nail beds blue
After 2 doses of 4 mg intranasal naloxone, given 3 minutes apart in alternating nostrils — breathing spontaneously, RR 14, rousable but agitated
ED vitals — HR 104 · BP 146/88 · RR 16 · T 37.1 °C · SpO2 96% on room air · GCS 14
History from sister — injects heroin; released from jail 11 days ago; used "the same amount he always used to"
Day 2 on the unit — lacrimation, rhinorrhea, gooseflesh, myalgia, vomiting, diarrhea, yawning; pupils now dilated; COWS 14
Q1 Select all that apply
Which findings at the scene indicate opioid overdose? Select all that apply.
  1. A. Pinpoint pupils
  2. B. Respiratory rate of 4 with gurgling breathing
  3. C. Unrousable to sternal rub
  4. D. Blue lips and nail beds
  5. E. Temperature 37.1 °C
Reveal answer & rationale
Answer: A, B, C, D
The sourced signs of opioid overdose are "unconsciousness or inability to awaken" (C), "pinpoint pupils" (A), "slow, shallow breathing; breathing difficulty manifested by choking sounds or a gurgling/snoring noise from a person who cannot be awakened; or respiratory arrest" (B), and "fingernails or lips turning blue or purple" (D). The miosis also carries diagnostic weight in its own right, since "the presence of miosis in a prehospital patient with altered mental status is highly indicative of responsiveness to naloxone." A normal temperature (E) is expected and requires no action here — hyperthermia belongs to the stimulant toxidrome, where it is muscular in origin and must not be treated with an antipyretic.
Q2 Multiple choice
The patient wakes after naloxone and is briefly combative. The nurse should recognize that:
  1. A. The naloxone dose was too low and should be repeated immediately
  2. B. This is precipitated withdrawal, which is an expected effect of reversal — provide safety, reassurance and explanation
  3. C. The patient is exhibiting drug-seeking behavior and should be discharged once calm
  4. D. A benzodiazepine should be given routinely to any patient who is agitated after naloxone
Reveal answer & rationale
Answer: B
Precipitated withdrawal (B) is the predicted effect: "the most common adverse effects associated with naloxone occur after acute withdrawal from opioids," including anxiety and aggression, and full reversal "can result in withdrawal and include combative or aggressive behavior." The sourced nursing response is exactly "provide safety, reassurance, and explain what is happening." Repeating the dose (A) misreads the goal, which is "adequate spontaneous respiration and oxygenation, but not full reversal" — he is already breathing at 16. Labelling it drug-seeking (C) mistakes a pharmacological effect for a behaviour, and discharging him at all here would fail the sourced criteria. Routine benzodiazepines (D) are not indicated in this setting, and their use alongside opioids carries a specific co-prescribing caution.
Q3 Put in order
Put the nurse’s actions in order for this patient:
  1. A. Arrange linked referral for continuing treatment and give naloxone plus teaching to the patient and his sister
  2. B. Monitor for re-sedation, knowing naloxone’s half-life is shorter than the opioid
  3. C. Score COWS serially and hold buprenorphine until the score exceeds 10
  4. D. Replace fluids and control the vomiting and diarrhea
Reveal answer & rationale
Correct order: B → D → C → A
Monitoring for re-sedation (B) comes first because naloxone’s half-life is only 30 to 80 minutes and is shorter than methadone, fentanyl and buprenorphine — a patient who stops breathing again is the immediate threat. Volume replacement and symptom control (D) follow on day 2, because vomiting, diarrhea and sweating together are the sourced hazard of opioid withdrawal and patients "should be monitored for dehydration and have fluid levels maintained." COWS scoring (C) then gates the buprenorphine, which must wait until the score exceeds 10 to avoid precipitating the very withdrawal it treats. The discharge package (A) is genuinely the action most likely to keep him alive — half to three quarters of people who complete withdrawal management never enter treatment — but it can only be built once he is stable.
Q4 Multiple choice
A different patient arrives agitated, febrile at 40.5 °C, tachycardic and hypertensive after using methamphetamine. Which action is contraindicated?
  1. A. Administering a parenteral benzodiazepine for sedation
  2. B. Applying physical restraints to control the agitation
  3. C. Using external cooling blankets and intravenous fluids
  4. D. Obtaining a creatine kinase and lactic acid level
Reveal answer & rationale
Answer: B
Physical restraints (B) are contraindicated, and the mechanism is given with the rule: "physical restraints should be avoided because clients who physically struggle against restraints undergo isometric muscle contractions that are associated with lactic acidosis, hyperthermia, sudden cardiac collapse, and death." Parenteral benzodiazepine sedation (A) is first-line, named by four separate sources, and it lowers temperature, blood pressure and heart rate together. External cooling and fluids (C) are the sourced method — and note that an antipyretic would be the other wrong answer, because "the increased body temperature is caused by muscular activity, not an alteration in the hypothalamic temperature set point." Creatine kinase and lactate (D) are explicitly recommended to identify "muscle damage and tissue ischemia related to tonic-clonic seizures, myoclonus, or hyperthermia."
Q5 Multiple choice
Which statement by the patient’s sister indicates that discharge teaching has been effective?
  1. A. "Now that he has finished detox, the hardest part is behind him."
  2. B. "If he uses again, the amount he used before jail could kill him now, so I am keeping the naloxone where I can reach it."
  3. C. "If the naloxone wakes him up, we can stay home and watch him."
  4. D. "He should be able to stop the buprenorphine once he feels better in a few weeks."
Reveal answer & rationale
Answer: B
The tolerance statement (B) captures the single most lethal fact on this page: "because withdrawal management reduces acquired tolerance, those who attempt to reuse their former substance in the same amount or frequency may overdose," and about 10% of overdose deaths involved someone recently released from an institution who was "unaware of decreased tolerance." Keeping naloxone accessible matters because a bystander was present in nearly 40% of overdose deaths. Option A inverts the truth: withdrawal management "by itself is not an effective treatment… it is considered stabilization," and the period right after it is the highest-risk window. Option C contradicts the instruction to "get the person to an emergency department… even if the person revives after the initial dose of naloxone and seems to feel better," since naloxone lasts 30 to 80 minutes. Option D misstates duration, which is contested — some clinicians stop at a year, others advise lifelong treatment — and stopping is never governed by feeling better.

Common questions

What causes substance use & overdose?
Common causes and risk factors include opioid use disorder crosses every demographic — it "occurs in individuals from all educational and socioeconomic backgrounds", chronic opioid therapy — "up to 50% of patients on chronic opioid therapy meet the criteria for opioid use disorder"; the prescribing lever is the cdc caution against escalating beyond 50 morphine milligram equivalents per day, family history — first-degree relatives with a substance use disorder — and a deficiency in neurotransmitters such as dopamine, untreated depression, post-traumatic stress disorder, anxiety or childhood trauma — named individual risk factors, and a documented mental health diagnosis was present in 25% of overdose deaths, environmental exposure — peer use of opioids, or exposure to opioid analgesics after a previous injury, and others.
Which findings should a nurse report immediately in substance use & overdose?
Report immediately: The opioid triad — pinpoint pupils, slow shallow breathing, and an unrousable patient, Respiratory depression — the one sign that triggers naloxone, Dilated pupils with tachycardia, hypertension, diaphoresis and agitation, Severe agitation that becomes violent without provocation, Hyperthermia in a stimulant-intoxicated patient, and others. These signal deterioration that needs rapid intervention.
Which medications are used to treat substance use & overdose?
Commonly prescribed drug classes include Opioid Analgesics, CNS Stimulants (ADHD), Benzodiazepines, Antiemetics — each is covered in depth in the pharmacology course.
Why is the period right after detox the most dangerous time?
Because tolerance falls and the remembered dose does not. "Because withdrawal management reduces acquired tolerance, those who attempt to reuse their former substance in the same amount or frequency may overdose, especially those with opioid use disorders." The risk is quantified from two directions: patients "are at the highest risk for opioid-related death in the first 4 weeks of OUD treatment and for 4 weeks after treatment ends," with the peak being "the period between detoxification and the start of maintenance therapy" — and about 10% of overdose deaths involved someone recently released from jail, prison, inpatient rehabilitation or a psychiatric hospital, specifically because they were "unaware of decreased tolerance to the drug due to abstinence while in the institution." The same physiology applies after any hospital admission. It is also why detoxification alone is not treatment: "half to three quarters of individuals… who receive withdrawal management services do not enter treatment," and "one of the most serious consequences when individuals do not begin continuing care after withdrawal management is overdose."
How much naloxone, and when do you stop watching?
Titrate to breathing, not to wakefulness. "The dose is titrated to increase the patient’s respiratory drive and allow for adequate spontaneous respiration and oxygenation, but not full reversal — this can result in withdrawal and include combative or aggressive behavior." Start at 0.04 to 0.1 mg IV in a known opioid-dependent patient and 0.4 mg in someone without known dependency, repeating every 2 to 3 minutes in alternating nostrils for the intranasal device or every 2 to 5 minutes for longer-acting opioids, with an infusion in some cases. You stop watching much later than you would think. Naloxone’s half-life is 30 to 80 minutes, shorter than methadone, fentanyl and buprenorphine, so monitor at least 4 hours from the last dose per the nursing text or 6 to 12 hours per StatPearls, longer for long-acting opioids — and discharge requires the full checklist, including a Glasgow coma scale of 15, no further naloxone needed, saturation at least 92% on room air, respiratory rate at least 10, and someone to monitor the patient for 12 to 24 hours. If repeated doses produce no response at all, "providers must consider other causes of unconsciousness."
Why can buprenorphine not be given as soon as the patient asks for it?
Because it is a partial agonist, and giving it too early causes the problem it is meant to treat. Withdrawal "can… be caused when a patient has an opioid in his/her system and is given an opioid partial agonist like buprenorphine or antagonists like naloxone or naltrexone," and it "can precipitate withdrawal in opioid-dependent patients who are NOT experiencing any withdrawal symptoms." So the patient must already be in mild to moderate withdrawal — a COWS score greater than 10 — or, by the clock, 12 to 18 hours after a short-acting agonist such as heroin or oxycodone and 24 to 48 hours after a long-acting one such as methadone. The first dose is typically 2 to 4 mg sublingually. Methadone is the opposite and is worth learning as the contrast: it "does not induce withdrawal symptoms when administered to a client with opioid in their system because it has an additive effect on opioids that are already present." And naltrexone is stricter still — it "may only be initiated when the patient is free of physiological opioid dependence, and at least seven days without acute withdrawal symptoms are required."

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.